UniQuest — University of Queensland's Commercialisation Company

UniQuest is the University of Queensland's wholly owned commercialisation company, established in 1984 to patent, license and spin out research from UQ; a $5 million investment in 1996 helped it grow into one of Australia's largest university technology-transfer operations at a time when few other Australian universities were commercialising research at scale.

UniQuest manages UQ's intellectual-property portfolio, files and prosecutes patents, negotiates licences with industry, and creates and holds equity in spin-out companies built on university research, spanning biotech, agtech and engineering.

Over four decades, UniQuest has been granted more than 360 US patents and formed more than 130 start-up companies from UQ intellectual property, which have collectively raised more than AUD$1 billion and generated more than AUD$86 billion in cumulative product sales. Its best-known success is the HPV vaccine Gardasil — patented in 1991 and licensed to CSL Limited in 1994 — alongside large exits such as Spinifex Pharmaceuticals and Inflazome. In July 2025, Sanofi agreed to acquire Vicebio, a company UniQuest helped spin out in 2018 around UQ's Molecular Clamp vaccine-stabilisation technology (developed by Professors Paul Young, Daniel Watterson and Keith Chappell), for a total upfront payment of US$1.15 billion plus up to US$450 million in milestones — confirmed in Sanofi's own press release as the largest deal ever involving intellectual property from an Australian university.

The Vicebio deal is independently verified by the acquirer itself (Sanofi) and international wire services, not just by UQ's own communications, giving unusually solid third-party confirmation of outcome value; four decades of continuous, growing commercialisation activity — spanning a globally significant vaccine (Gardasil) to a 2025 billion-dollar exit — demonstrate durable institutional capability, though the historic cumulative sales and fundraising figures remain UniQuest's own self-reported tallies.

Read the full analysis: https://uniquest.com.au/about/

Read the full analysis: https://uniquest.com.au/about/